Skip to search formSkip to main contentSkip to account menu

Alpelisib

An orally bioavailable phosphatidylinositol 3-kinase (PI3K) inhibitor with potential antineoplastic activity. Alpelisib specifically inhibits PI3K in… 
National Institutes of Health

Related topics

Related topics

2 relations

Narrower (1)

BYL719
NCIt Antineoplastic Agent Terminology

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Abstract OT1-03-01: Phase 1/1b study of novel oral selective estrogen receptor degrader (SERD) LSZ102 in combination with alpelisib (BYL719) in estrogen receptor-positive (ER+), human epidermal…
Background: Although ET remains the basis of therapy for ER+, HER2– ABC, treatment resistance frequently occurs. Novel strategies… 
2018
2018
Alpelisib Extends PFS in PIK3CA-Mutant Breast Cancer.
In a phase III trial, patients with PIK3CA-mutant advanced breast cancer benefited from taking the PI3Kα inhibitor alpelisib in… 
2018
2018
Abstract P5-21-06: Alpelisib plus letrozole in estrogen receptor-Positive (ER+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (aBC): Safety and preliminary…
Background Endocrine therapy is the standard first-line treatment for postmenopausal patients (pts) with ER+, HER2– aBC. However… 
2018
2018
Abstract OT3-05-02: BYLieve: A phase 2 study of alpelisib with fulvestrant or letrozole for treatment of PIK3CA mutant, hormone receptor-positive (HR+), human epidermal growth factor receptor 2…
Background: Endocrine therapy (ET) is the standard of care for treatment of HR+, HER2– aBC. However, ET resistance occurs… 
Review
2017
Review
2017
Abstract OT2-01-04: SOLAR-1: A phase III study of alpelisib and fulvestrant in men and postmenopausal women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative…
Background: The phosphatidylinositol 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) pathway is often dysregulated in HR+ BC… 
2016
2016
Abstract P4-13-27: A phase Ib dose de-escalation study of combined tamoxifen and goserelin acetate with alpelisib (BYL719) or buparlisib (BKM120) in premenopausal patients with HR+/HER2– locally…
Background: Growing evidence suggests that concomitant inhibition of the phosphatidylinositol 3-kinase (PI3K)/AKT/mammalian… 
2015
2015
Abstract CT136: Final biomarker analysis of the phase I study of the selective BRAF V600 inhibitor encorafenib (LGX818) combined with cetuximab with or without the α-specific PI3K inhibitor alpelisib…
Background: Although BRAF V600-mutated (BRAFm) colorectal carcinoma (CRC) does not generally respond to BRAF inhibitors, results… 
2015
2015
A Phase II study of the safety and efficacy of alpelisib or buparlisib plus letrozole in neoadjuvant treatment of postmenopausal women with HR+/HER2–, PIK3CA mutant or wild-type breast cancer.
TPS633 Background: The PI3K/AKT/mTOR pathway is the most frequently activated signaling pathway in breast cancer (BC). PIK3CA… 
2015
2015
Drug combo beneficial in colorectal cancer.
The BRAF V600E mutation, well documented in melanoma, is also present in approximately 8% of patients with colorectal cancer… 
Review
2015
Review
2015
Alpelisib. Phosphatidylinositol 3-kinase alpha (PI3K alpha) inhibitor Oncolytic
Phosphatidylinositol 4,5-bisphosphate 3-kinases (PI3Ks) play a central role in numerous biological processes (such as cell death…